A comparison of the labeling of antineoplastic and supportive medicines in China, Japan, and the US based on the WHO essential medicines list
There were significant differences in the safety information on drug labels in China, Japan, and the US from the same manufacturer, which could pose a risk to patients. Regulatory agencies should better align their approaches to labeling to prevent confusion or misunderstanding across regions.
Authors
- Chenyu Du (ORCID: https://orcid.org/0000-0002-8095-5848)
- Caiyi Wang (ORCID: https://orcid.org/0000-0002-6317-3916)
- Jiaxin Liu (ORCID: https://orcid.org/0000-0001-5993-9221)
- Pengcheng Liu (ORCID: https://orcid.org/0000-0001-8775-6334)
Institutions
- China Pharmaceutical University (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-11-20
- DOI
- https://doi.org/10.3389/fmed.2025.1600207
- Primary Topic
- Pharmaceutical studies and practices
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Southern California